COLL · Collegium Pharmaceutical, Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Belbuca net revenue | $52.6M | the quarter ended March 31, 2026 | +1.8% |
|
|
|||
| JORNAY PM net revenue | $38.9M | the quarter ended March 31, 2026 | +36.3% |
|
|
|||
| Pain portfolio net revenues | $154.6M | the quarter ended March 31, 2026 | — |
|
|
|||
| Xtampza ER net revenue | $50.8M | the quarter ended March 31, 2026 | +6.6% |
|
|
|||
| Adjusted earnings per share non-GAAP | $7.42 | FY 2025 | — |
| Jornay PM prescribers | 29,000 | Q4 2025 | — |
| Jornay PM prescriptions | 760,000 | FY 2025 | — |
| Nucynta Franchise net revenue | $196.3M | FY 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COLL
this stock
Collegium Pharmaceutical, Inc
|
$1.15B | -23.2% | +23.6% | 17.4 | 16.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.75B | +8.0% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.10B | +3.7% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.16B | -3.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COLL | +0.2% | -5.0% | -23.1% | +0.5% | -23.2% |
| SPY | +2.5% | +0.9% | +9.2% | +1.4% | +11.1% |
| vs SPY | -2.3% | -5.9% | -32.3% | -0.9% | -34.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.